文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

体外膜氧合治疗COVID-19:系统评价与荟萃分析

Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2021-06-14
一句话结论在COVID-19相关ARDS成人中,接受ECMO支持者院内合并死亡率为37.1%(95%CI 32.3-42.0%,高确定性证据),以静脉-静脉ECMO为主(98.6%)。

该研究检索MEDLINE、Embase、Cochrane和Scopus数据库2019年12月1日至2021年1月10日的观察性研究或随机临床试验,纳入22项观察性研究、1896例成人COVID-19 ARDS患者,采用随机效应模型进行荟萃分析与meta回归,并以GRADE评级证据确定性。以静脉-静脉ECMO为主(98.6%),院内合并死亡率37.1%(95%CI 32.3-42.0%,高确定性),静脉-静脉ECMO组35.7%(95%CI 30.7-40.7%,高确定性);ECMO支持时长15.1天(95%CI 13.4-18.7),脱机率67.6%(95%CI 50.5-82.7%),共报告1583例次并发症,以肾脏并发症最常见。meta回归显示年龄与ECMO时长与死亡增加相关。作者认为静脉-静脉ECMO对经过选择的COVID-19相关ARDS患者似乎是有效干预。

要点

  • 22项观察性研究、1896例成人COVID-19 ARDS患者,ECMO支持者院内合并死亡率37.1%(95%CI 32.3-42.0%,高确定性证据)。
  • 静脉-静脉ECMO为主要模式(98.6%),该组院内合并死亡率35.7%(95%CI 30.7-40.7%,高确定性)。
  • ECMO支持时长15.1天(95%CI 13.4-18.7,18项研究、1844例),脱机率67.6%(95%CI 50.5-82.7%,17项研究、1412例)。
  • 18项研究、1721例患者共报告1583例次ECMO并发症,肾脏并发症最常见。
  • meta回归显示年龄增加与ECMO时长与死亡率升高相关。

适用人群与场景

  • 成人COVID-19相关急性呼吸窘迫综合征(ARDS)患者,来自22项观察性研究或随机临床试验,纳入荟萃分析共1896例。
  • 以静脉-静脉ECMO为主要支持模式,占98.6%。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,检索MEDLINE、Embase、Cochrane和Scopus数据库2019年12月1日至2021年1月10日的观察性研究或随机临床试验;采用随机效应meta分析与meta回归,偏倚风险用Joanna Briggs研究所清单评估,证据确定性用GRADE评级。
  • 纳入22项观察性研究、1896例患者;静脉-静脉ECMO为主要模式(98.6%)。
  • 主要终点:ECMO支持的COVID-19患者院内合并死亡率为37.1%(95%CI 32.3-42.0%,高确定性);静脉-静脉ECMO组为35.7%(95%CI 30.7-40.7%,高确定性)。
  • 次要终点:ECMO支持时长15.1天(95%CI 13.4-18.7;18项研究、1844例);脱机率67.6%(95%CI 50.5-82.7%;17项研究、1412例);18项研究、1721例患者共报告1583例次ECMO并发症,肾脏并发症最常见。
  • meta回归:年龄与ECMO时长与死亡率升高相关。
  • 作者结论:COVID-19接受ECMO支持者院内死亡率37.1%,与大流行第一年非COVID-19相关ARDS者相似;年龄增加是死亡的危险因素。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入22项观察性研究;证据确定性采用GRADE评级,院内死亡率与静脉-静脉ECMO组死亡率为高确定性。

对床旁实践的改变

  • 作者认为,静脉-静脉ECMO对经过选择的COVID-19相关ARDS患者似乎是有效干预;本资料可用于与家属沟通ECMO支持者的院内死亡风险(合并37.1%,静脉-静脉组35.7%)。
  • meta回归提示年龄增加与ECMO时长与死亡增加相关,可作为评估预后时参考的原文结论。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There are several reports of extracorporeal membrane oxygenation (ECMO) use in patients with coronavirus disease 2019 (COVID-19) who develop severe acute respiratory distress syndrome (ARDS). We conducted a systematic review and meta-analysis to guide clinical decision-making and future research.

METHODS: We searched MEDLINE, Embase, Cochrane and Scopus databases from 1 December 2019 to 10 January 2021 for observational studies or randomised clinical trials examining ECMO in adults with COVID-19 ARDS. We performed random-effects meta-analyses and meta-regression, assessed risk of bias using the Joanna Briggs Institute checklist and rated the certainty of evidence using the GRADE approach. Survival outcomes were presented as pooled proportions while continuous outcomes were presented as pooled means, both with corresponding 95% confidence intervals [CIs]. The primary outcome was in-hospital mortality. Secondary outcomes were duration of ECMO therapy and mechanical ventilation, weaning rate from ECMO and complications during ECMO.

RESULTS: We included twenty-two observational studies with 1896 patients in the meta-analysis. Venovenous ECMO was the predominant mode used (98.6%). The pooled in-hospital mortality in COVID-19 patients (22 studies, 1896 patients) supported with ECMO was 37.1% (95% CI 32.3-42.0%, high certainty). Pooled mortality in the venovenous ECMO group was 35.7% (95% CI 30.7-40.7%, high certainty). Meta-regression found that age and ECMO duration were associated with increased mortality. Duration of ECMO support (18 studies, 1844 patients) was 15.1 days (95% CI 13.4-18.7). Weaning from ECMO (17 studies, 1412 patients) was accomplished in 67.6% (95% CI 50.5-82.7%) of patients. There were a total of 1583 ECMO complications reported (18 studies, 1721 patients) and renal complications were the most common.

CONCLUSION: The majority of patients received venovenous ECMO support for COVID-19-related ARDS. In-hospital mortality in patients receiving ECMO support for COVID-19 was 37.1% during the first year of the pandemic, similar to those with non-COVID-19-related ARDS. Increasing age was a risk factor for death. Venovenous ECMO appears to be an effective intervention in selected patients with COVID-19-related ARDS. PROSPERO CRD42020192627.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Ramanathan K, Shekar K, Ling RR, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care. 2021. PMID: 34127027. doi:10.1186/s13054-021-03634-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。